278 related articles for article (PubMed ID: 30963763)
1. Targeting the Thioredoxin System as a Strategy for Cancer Therapy.
Bian M; Fan R; Zhao S; Liu W
J Med Chem; 2019 Aug; 62(16):7309-7321. PubMed ID: 30963763
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Thioredoxin System for Cancer Therapy.
Zhang J; Li X; Han X; Liu R; Fang J
Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
[TBL] [Abstract][Full Text] [Related]
3. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
4. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase.
Zhang J; Yao J; Peng S; Li X; Fang J
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):129-138. PubMed ID: 27777067
[TBL] [Abstract][Full Text] [Related]
5. The thioredoxin system and cancer therapy: a review.
Mohammadi F; Soltani A; Ghahremanloo A; Javid H; Hashemy SI
Cancer Chemother Pharmacol; 2019 Nov; 84(5):925-935. PubMed ID: 31367788
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin-dependent system. Application of inhibitors.
Jastrząb A; Skrzydlewska E
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):362-371. PubMed ID: 33356659
[TBL] [Abstract][Full Text] [Related]
7. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin reductase inhibitors: a patent review.
Zhang B; Zhang J; Peng S; Liu R; Li X; Hou Y; Han X; Fang J
Expert Opin Ther Pat; 2017 May; 27(5):547-556. PubMed ID: 27977313
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of mammalian thioredoxin reductase.
Cai W; Zhang L; Song Y; Wang B; Zhang B; Cui X; Hu G; Liu Y; Wu J; Fang J
Free Radic Biol Med; 2012 Jan; 52(2):257-65. PubMed ID: 22064364
[TBL] [Abstract][Full Text] [Related]
10. The role of thioredoxin system in cancer: strategy for cancer therapy.
Jia JJ; Geng WS; Wang ZQ; Chen L; Zeng XS
Cancer Chemother Pharmacol; 2019 Sep; 84(3):453-470. PubMed ID: 31079220
[TBL] [Abstract][Full Text] [Related]
11. Thioredoxin system modulation by plant and fungal secondary metabolites.
Dal Piaz F; Braca A; Belisario MA; De Tommasi N
Curr Med Chem; 2010; 17(5):479-94. PubMed ID: 19941471
[TBL] [Abstract][Full Text] [Related]
12. Thiol antioxidant thioredoxin reductase: A prospective biochemical crossroads between anticancer and antiparasitic treatments of the modern era.
Joardar N; Guevara-Flores A; Martínez-González JJ; Sinha Babu SP
Int J Biol Macromol; 2020 Dec; 165(Pt A):249-267. PubMed ID: 32961182
[TBL] [Abstract][Full Text] [Related]
13. A diterpenoid derivate compound targets selenocysteine of thioredoxin reductases and induces Bax/Bak-independent apoptosis.
Liu J; Mu C; Yue W; Li J; Ma B; Zhao L; Liu L; Chen Q; Yan C; Liu H; Hao X; Zhu Y
Free Radic Biol Med; 2013 Oct; 63():485-94. PubMed ID: 23732520
[TBL] [Abstract][Full Text] [Related]
14. Selenadiazole derivatives as potent thioredoxin reductase inhibitors that enhance the radiosensitivity of cancer cells.
Liang YW; Zheng J; Li X; Zheng W; Chen T
Eur J Med Chem; 2014 Sep; 84():335-42. PubMed ID: 25036792
[TBL] [Abstract][Full Text] [Related]
15. Effects of Mammalian Thioredoxin Reductase Inhibitors.
Arnér ESJ
Handb Exp Pharmacol; 2021; 264():289-309. PubMed ID: 32767140
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
17. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
19. B5, a thioredoxin reductase inhibitor, induces apoptosis in human cervical cancer cells by suppressing the thioredoxin system, disrupting mitochondrion-dependent pathways and triggering autophagy.
Shao FY; Du ZY; Ma DL; Chen WB; Fu WY; Ruan BB; Rui W; Zhang JX; Wang S; Wong NS; Xiao H; Li MM; Liu X; Liu QY; Zhou XD; Yan HZ; Wang YF; Chen CY; Liu Z; Chen HY
Oncotarget; 2015 Oct; 6(31):30939-56. PubMed ID: 26439985
[TBL] [Abstract][Full Text] [Related]
20. Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
Kłossowski S; Muchowicz A; Firczuk M; Swiech M; Redzej A; Golab J; Ostaszewski R
J Med Chem; 2012 Jan; 55(1):55-67. PubMed ID: 22128876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
